11-47342745-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.1458-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,510 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000256.3 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.1458-1G>A | splice_acceptor_variant, intron_variant | Intron 16 of 34 | 5 | NM_000256.3 | ENSP00000442795.1 | |||
MYBPC3 | ENST00000399249.6 | c.1458-1G>A | splice_acceptor_variant, intron_variant | Intron 15 of 33 | 5 | ENSP00000382193.2 | ||||
MYBPC3 | ENST00000544791.1 | n.1458-1G>A | splice_acceptor_variant, intron_variant | Intron 16 of 26 | 5 | ENSP00000444259.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461510Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 727026
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Pathogenic:2
This sequence change affects an acceptor splice site in intron 16 of the MYBPC3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with hypertrophic cardiomyopathy and/or dilated cardiomyopathy (PMID: 22178992, 27532257, 27600940, 28615295, 30847666, 31514951; Invitae). ClinVar contains an entry for this variant (Variation ID: 42532). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
The c.1458-1G>A variant in MYBPC3 has been previously identified by our laborato ry in 1 adult with HCM. It was absent from large populations studies (dbSNP rs39 7515903). This variant occurs in the invariant region (+/- 1,2) of the splice co nsensus sequence and is predicted to cause altered splicing leading to an abnorm al or absent protein. Heterozygous loss of MYBPC3 function is an established me chanism of disease for HCM. In summary, this variant meets our criteria to be cl assified as pathogenic for HCM in an autosomal dominant manner (http://www.partn ers.org/personalizedmedicine/LMM) based upon predicted impact to the protein and absence from controls. -
Cardiomyopathy Pathogenic:1
- -
not provided Pathogenic:1
Not observed in large population cohorts (Lek et al., 2016); Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; Reported in ClinVar as pathogenic (ClinVar Variant ID# 42532; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 28408708, 28790153, 28615295, 27532257, 27600940, 22178992, 31514951) -
Cardiovascular phenotype Pathogenic:1
The c.1458-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide before coding exon 17 of the MYBPC3 gene. This alteration has been detected in hypertrophic cardiomyopathy (HCM) cohorts undergoing genetic testing (Walsh R et al. Genet. Med. 2017 Feb;19(2):192-203; Cecconi M et al. Int. J. Mol. Med. 2016 Oct;38(4):1111-24). Another alteration affecting the same nucleotide (c.1458-1G>C) has also been reported in a patient with HCM (van Dijk SJ et al. Circ Heart Fail. 2012;5(1):36-46). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
MYBPC3-related disorder Pathogenic:1
The MYBPC3 c.1458-1G>A variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant was reported in individuals with hypertrophic cardiomyopathy or dilated cardiomyopathy (Table S1b, Walsh et al. 2017. PubMed ID: 27532257; Online Table 1, Gigli et al. 2019. PubMed ID: 31514951). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Variants that disrupt the consensus splice acceptor site in MYBPC3 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at